Archives des études
Toutes les études
Page 11 sur 52 · 1235 études
43/100
XPeng: A Genuine Margin Recovery, But the Stock No Longer Prices Like a Distressed Turnaround
XPeng Inc. (XPEV.US) is a Guangzhou-based smart-EV maker whose 2025 recovery delivered RMB76.72 billion in revenue, an 18.9% gross margin, and its first-ever quarterly profit, before Q1 2026 revenue fell 17.6% year over year to a RMB1.78 billion loss even as gross margin held at 20.6%. The bull case rests on a reusable ADAS and Turing-chip software stack now extending into robotaxi, robotics and flying-car projects; the bear case is that China's EV price war remains brutal and these 'physical AI' bets could absorb management focus well before they generate returns. Rating Hold: the car business has genuinely improved, but at $12.33 the stock already sits inside the report's own acceptable-hold band, leaving little margin of safety beyond steady execution.
38/100
Kawasaki Heavy Industries: Aerospace Earned the Rerating, the Rest of the Group Still Has to Pay for It
Kawasaki Heavy Industries is a Japanese heavy-industrial conglomerate spanning aerospace and defense, energy and marine engineering, rolling stock, and robotics, with FY2025 revenue of ¥2,311.3 billion. Aerospace Systems has become the group's largest profit pool as Japan's defense build-up accelerates, with Ministry of Defense sales reaching ¥429.8 billion, but the July 2026 issuance of new shares and convertible bonds to fund aircraft engines, robotics and hydrogen projects dropped the stock roughly 7% and underscored how capital-hungry the rest of the group remains. Rating Hold: the aerospace-led rerating is real, but thin Rolling Stock margins, unproven hydrogen economics and fresh dilution leave today's price near fair value rather than a compelling entry point.
40/100
Shanghai Junshi Biosciences: A Real PD-1 Franchise, But the A-Shares Already Price an Unproven Profit Bridge
Shanghai Junshi Biosciences (688180.SHG) is a Chinese biopharma whose PD-1 antibody toripalimab now drives about 83% of group revenue, with 2025 revenue up 28.2% and Q1 2026 operating cash flow turning positive for the first time. The stock trades at roughly a 125% premium over its Hong Kong-listed H-shares (1877.HK) because Shanghai investors are pricing a bridge to durable, non-recurring-free profitability that management has not yet finished building. Rating Hold: commercial execution is improving fast, but the current A-share price already discounts much of that bridge, leaving little margin of safety.
40/100
Shanghai MicroPort MedBot: Commercial Traction Is Real, but the Re-Rating Has Already Happened
Shanghai MicroPort MedBot is a Chinese surgical-robotics developer whose Toumai laparoscopic platform and SkyWalker orthopedic robot have moved from clinical-trial promise into real commercial installations across more than 60 countries. FY2025 revenue rose 114.2% to RMB551.1 million with gross margin improving to 48.4% and free cash outflow shrinking sharply, and the company just guided to first-half 2026 profitability, but roughly 71% of 2025 revenue still ran through related-party sales with parent MicroPort and the stock already trades near 32 times trailing sales. Rating Hold: the commercial inflection is genuine, but at HK$20.22 the market has already re-rated the stock to price in much of that transition, leaving little margin of safety against any execution slip.
38/100
Rocket Pharmaceuticals: Cash Buys Time, but Danon Still Has to Earn Back the Market's Trust
Rocket Pharmaceuticals (RCKT.US) is a rare-disease gene-therapy developer whose sole approved product, Kresladi, still generates no revenue, leaving cash and a $180 million voucher sale as the real near-term story. The stock trades near the value of its cash alone because the market still distrusts the pivotal Danon cardiac program after a 2025 clinical hold, even though Phase 1 data and a modified lower-dose cohort keep the thesis alive. Rating Hold: cash buys time, but Danon still has to earn back trust and Kresladi is too small to carry the valuation on its own.
44/100
59Buffett
Jiangsu Hengli Hydraulic: A Real Compounder, but a Stock Already Pricing an Unproven Robot Story
Jiangsu Hengli Hydraulic (601100.SHG) is China's dominant hydraulic-components maker, still earning most of its profit from excavator cylinders, pumps and valves while building an early, largely undisclosed linear-motion and humanoid-robot-actuator business. 2025 revenue grew 16.5% and 2026 Q1 accelerated further, but cash conversion deteriorated sharply and the robot narrative still lacks separately disclosed revenue, backlog, or named customers. Rating Hold: a real hydraulics compounder trading inside its own fair-value band, with little margin of safety once optimism about the unproven robot story is priced in.
35/100
Absci Corporation: The Platform Is Real, but the Price Already Bets Big on ABS-201
Absci is a clinical-stage biotech that uses generative AI, proprietary high-throughput lab data, and wet-lab validation cycles to design antibodies, but current revenue still comes almost entirely from small, lumpy partnered discovery fees rather than owned products. FY2025 revenue was just $2.8 million and fell further to $0.2 million in Q1 2026, while the June 2026 announcement of positive interim Phase 1 safety data for lead asset ABS-201 (androgenetic alopecia) let the company raise $100 million, including a $40 million allocation from Eli Lilly, at $7.41 a share. Rating Hold: the platform and early clinical data are genuinely more credible than a year ago, but at $7.56 the stock already sits near a roughly $1.2-1.3 billion valuation on almost no current revenue, leaving little room for anything short of a strong ABS-201 efficacy readout.
41/100
Fujikura: A Real AI-Optics Profit Engine, but a Price That Leaves No Margin of Safety
Fujikura is a century-old Japanese cable manufacturer whose profit mix is now dominated by AI-datacenter optical fiber and cable, with the Information & Telecommunications segment producing 55% of FY2026 revenue and 81% of operating profit. FY2026 sales rose 20.7% to JPY 1,182.4 billion and operating profit 39.2% to a record JPY 188.7 billion, and a sharp June 2026 guidance revision (to JPY 1.462 trillion sales and JPY 310 billion operating profit for FY2027) pulled the company's own FY2028 mid-term target nearly into reach a year early, yet the roughly JPY 8.15 trillion market cap already exceeds Sumitomo Electric's despite a fraction of its revenue. Rating Watch: the AI-optics earnings are real and accelerating, but at JPY 4,593 the stock trades far above the report's conservative fair-value band of JPY 2,400-2,800, leaving no margin of safety.
43/100
Beijing Geekplus Technology: The AMR Core Is Real, the Humanoid Story Is Still Optionality
Beijing Geekplus Technology is a Beijing-founded, Hong Kong-listed warehouse-automation company that sells autonomous mobile robot (AMR) systems for warehouse fulfilment and industrial material handling, with 75.3% of 2025 revenue coming from outside mainland China. FY2025 revenue grew 31.6% to RMB3.171 billion, gross margin improved to 35.5%, and the company posted its first adjusted net profit of RMB43.8 million and positive operating cash flow of RMB85.7 million, even as statutory net income stayed negative RMB10.4 million and trade receivables grew faster than revenue. Rating Hold: the core AMR business is a proven, globally exportable operating model, but at HK$9.81 the stock still prices in more margin durability than the company has fully demonstrated, while the newer humanoid and embodied-intelligence narrative remains optionality rather than disclosed revenue.
43/100
Shenzhen Dobot: Real Cobot Business, Unproven Humanoid Bet
Shenzhen Dobot is a Hong Kong-listed collaborative-robot maker using its established industrial-automation business to fund a fast-growing but still small embodied-intelligence push into humanoids and quadrupeds. 2025 revenue grew 31.7% to RMB492.2 million with a narrowing net loss, but embodied-intelligence products were only about 4% of main-business revenue with margin slipping to 43.4% from 49.9%, while the company diluted shareholders twice in 2025 and is now pursuing a ChiNext A-share listing for further capital. Rating Hold: at HK$25.22 the stock sits near base-case fair value with no margin of safety against the conservative scenario, still pricing meaningful future execution rather than current profitability.
37/100
Furukawa Electric: A Real AI-Optics Transition the Market Has Already Priced In
Furukawa Electric is a diversified Japanese cable-and-electronics conglomerate whose profit mix is pivoting from legacy automotive-wire and metal businesses toward AI-datacenter optical cable, connectivity, and cooling products under its Lightera-branded optical unit. FY2025 sales reached JPY 1,307.6 billion with operating profit of JPY 63.9 billion, and FY2026 guidance calls for Optical Solutions and Digital Infrastructure Components operating profit to more than double, but FY2025 free cash flow was negative JPY 19.0 billion and the roughly JPY 2.48 trillion market cap already implies about 30 times FY2026 guided profit. Rating Watch: the datacenter-optics pivot is real and already visible in segment guidance, but at JPY 3,513 the stock trades well above the report's base-case fair value of JPY 2,100-2,800, leaving no margin of safety.
47/100
Yuanjie Semiconductor: Real AI-Optics Growth, Zero Margin of Safety
Yuanjie is an upstream IDM laser-chip maker whose product mix flipped from telecom toward AI-driven data-center silicon-photonics CW light sources, lifting 2025 revenue to CNY 601.4 million (gross margin to 58.15%) and driving 2026 H1 guidance up 339-364% year on year. But the same filings show its largest customer alone supplied 53.35% of 2025 sales (up from 16.38% in 2024), the CNY 1.251 billion phase-two expansion withholds its capacity target, and part of the H1 2026 profit surge is non-recurring fair-value gains. Rating Avoid: at CNY 1,445 the stock already prices in years of flawless scaling above even this report's own optimistic CNY 1,180/share fair-value estimate, with a margin-of-safety verdict of none.
36/100
Plug Power: A Real Turnaround With Zero Margin of Safety
Plug Power is a vertically integrated hydrogen platform selling fuel-cell systems, electrolyzers and hydrogen supply, still trying to prove that owning the whole stack creates value rather than just multiplying capital needs. FY2025 revenue reached about $710 million and gross margin turned positive for the first time in Q4 2025, but slid back to negative 13.2% in Q1 2026 while unrestricted cash fell from $368.5 million to a preliminary $162 million by June 30, keeping dilution risk from the ATM and Yorkville programs very much alive, and the DOE's $1.66 billion loan remains suspended rather than functioning as a funding backstop. Rating Watch: real operating progress, but at $2.19 the stock already sits above the report's own $1.25 conservative fair-value estimate with zero margin of safety.
34/100
Generate Biomedicines: The Asset Is Real, the AI Premium Is Still on Trial
Generate Biomedicines is a clinical-stage generative-biology company designing AI-generated protein therapeutics, funding its lead Phase 3 severe-asthma asset GB-0895 from Novartis and Amgen collaboration revenue and a post-IPO cash balance of $516.6 million as of March 2026. The core tension: Q1 2026 collaboration revenue fell to $7.2 million from $8.8 million a year earlier while net loss widened to $61.7 million and operating cash burn reached $80.4 million, so nearly all of the company's value now rests on one late-stage asset that will not complete enrollment until the first half of 2028, even as the stock still trades about 13% below its February 2026 IPO price. Rating Hold: the platform science and cash runway are real, but at $13.90 the market has already priced in a meaningful share of GB-0895's eventual success, leaving little margin of safety for new capital.
36/100
CGN Power: A Real Nuclear Moat, but No Margin of Safety Yet
CGN Power is China's listed nuclear-generation platform under China General Nuclear Power Group, operating 28 reactors with 31.838 GW of capacity at year-end 2025 and one of the industry's largest build-out pipelines, 18 units still under construction as of mid-2026. The core tension: 2025 revenue fell 4.1% to RMB 75.70 billion and Q1 2026 revenue dropped a further 13.25% as refuelling outages hit availability even as market-based tariffs fell about 8.8%, though half-year 2026 data show the decline sharply narrowing as Q2 generation recovered year on year. Rating Hold: a genuine state-backed nuclear moat with a real multi-year build-out runway, but at CNY 4.11 (about 22.5x trailing earnings) the A-shares already price in much of that story with no large margin of safety.
49/100
63Buffett
Rheinmetall: Respect Without Urgency for a Re-Rated Defence Prime
Rheinmetall is Germany's dominant defence prime, an ammunition-and-land-systems specialist riding a record €73.0bn backlog as European rearmament accelerates past €380bn in 2025 defence spending. FY2025 continuing sales rose to €9.94bn at an 18.5% margin, led by a 29.3% margin in the core Weapon and Ammunition unit, but June's abrupt cancellation of the F126 frigate programme wiped out nearly a fifth of the share price in a single day, exposing how much of the celebrated backlog is framework rather than firm order intake. Rating Hold: a genuinely stronger, cleaner defence business than it was two years ago, but a stock still priced at roughly 40x earnings for execution that has not yet been proven immune to political reversal.
48/100
48Buffett
Ningbo Tuopu: Fair for the Auto Business, Pricey for the Robot Option
Ningbo Tuopu is a diversified Chinese Tier 0.5/Tier 1 auto-parts supplier spanning chassis, interior, NVH, thermal management and an early-stage robot-actuator business, with 2025 revenue of CNY 29.58 billion under a founder-controlled ownership structure. The core tension: revenue grew 11.2% in 2025 and 14.9% again in Q1 2026, but attributable profit growth has stalled even as the stock trades near 30x trailing earnings on hopes for a humanoid-robotics ramp that primary filings do not yet support — robot-actuator revenue was only CNY 13.6 million in 2025, under one-twentieth of one percent of group sales. Rating Hold: the auto platform earns a fair multiple on its own, but fresh capital is still paying for a robotics option that has not shown up in the numbers.
47/100
Sichuan Baili Tianheng: A De-Risked ADC Story the Market Has Already Priced In
Sichuan Baili Tianheng (STAR Market 688506, English IR name Sichuan Biokin) is a China-listed oncology biotech whose legacy generics business in anesthesia, parenteral nutrition and traditional Chinese medicine still funds operations, but whose roughly CNY 141 billion market value is now dominated by iza-bren (BL-B01D1), a first-in-class bispecific EGFR×HER3 ADC licensed to Bristol Myers Squibb for $800 million upfront plus billions more in potential milestones. The core tension: 2024 revenue and profit spiked on that upfront payment (revenue up 936% to CNY 5.82 billion), then reverted to a CNY 1.05 billion net loss in 2025 as licensing income normalized, and Q1 2026 still burned CNY 741.8 million of operating cash against just CNY 94.6 million of revenue, all while iza-bren was winning FDA Breakthrough Therapy Designation and its first two China approvals in 2026. Rating Hold: a genuinely de-risked, first-in-class ADC franchise, but at CNY 329.69 the shares already sit near the middle of a reasonable fair-value band with no obvious margin of safety.
36/100
54Buffett
Sanmina Corporation
Sanmina Corporation is a diversified U.S. electronics manufacturing services (EMS) provider whose legacy industrial, medical, and communications manufacturing base was reset upward by the October 2025 acquisition of AMD's ZT Systems data-center manufacturing business. Fiscal Q2 2026 revenue jumped to 4.01 billion USD from 1.98 billion USD a year earlier on accelerated AI-server shipments, but management said some second-half volume pulled forward, and Q3 guidance of 3.2 to 3.5 billion USD sits well below that peak. Rating Hold: the balance sheet now carries 2.17 billion USD of acquisition-related debt, customer concentration remains high (two customers each above 10% of sales), and the current 219.41 USD price already discounts much of the AI-driven re-rating before its durability is proved.
45/100
Tianshui Huatian: A Transition Story the Market Is Already Paying For
Tianshui Huatian is a leading mainland Chinese OSAT (outsourced semiconductor assembly and test) company, packaging and testing chips for automotive, memory, RF and consumer customers from a manufacturing network spanning Tianshui, Xi'an, Kunshan, Nanjing, and Unisem in Malaysia. The core tension: 2025 revenue rose 19.0% to CNY 17.21 billion and net profit grew 15.3% to CNY 711 million, but recurring profit was only CNY 200.4 million once subsidies and fair-value gains are stripped out, while 2025 capex of CNY 6.15 billion far outran operating cash flow — even as the stock traded near 86x trailing earnings after repeated limit-up moves tied to an advanced-packaging and AI narrative. Rating Hold: the packaging upgrade is real, but owner earnings haven't caught up to a price that already assumes it succeeds.
44/100
39Buffett
Telefonaktiebolaget LM Ericsson
Telefonaktiebolaget LM Ericsson is a Swedish telecom-equipment vendor whose revenue still leans on mobile radio-access-network hardware, layered with a high-margin patent-licensing stream and an emerging AI-in-RAN software push. 2025 sales reached SEK 236.7 billion with gross margin recovering to 47.6%, but the July 2026 sell-off, down about 18% in five trading days after a working-capital scare, shows the stock still trades like a cyclical hardware name. Rating Hold: the balance sheet is strong and the repair story is real, but AI-in-RAN monetization remains early and the current SEK 92.80 price does not yet offer enough margin of safety.
40/100
60Buffett
Flex Ltd: The CPI Spin-Off Is Real, But the Stock Has Already Front-Run the Rerating
Flex Ltd is a Singapore-domiciled contract manufacturer now split into two identities under one ticker: a diversified electronics manufacturer serving healthcare, industrial, and communications customers, and a fast-growing Cloud and Power Infrastructure (CPI) arm supplying power, cooling, and cloud hardware for AI data centers, slated for a tax-free spin-off targeted for the first quarter of calendar 2027. Fiscal 2026 revenue reached 27.9 billion USD, with CPI alone growing 38% to 6.6 billion USD at a 9.2% adjusted operating margin, well above the 5.4%-6.0% margins of the legacy segments, while the stock already trades around 55x trailing GAAP earnings and 29x the midpoint of fiscal 2027 adjusted EPS guidance. Rating Hold: the spin-off thesis is real, but today's price already capitalizes much of the post-separation rerating before the final capital structure and standalone disclosures are public.
44/100
38Buffett
MasTec, Inc.
MasTec is a U.S. specialty infrastructure contractor spanning telecom fiber, utility power delivery, gas pipelines, and heavy civil work, now pushing further into data-center electrical systems through its 2026 Superior acquisition. Record 2025 revenue of 14.3 billion USD and an all-time-high 19.0 billion USD backlog justify the recent re-rating, but at 351.40 USD the market is already pricing smooth Superior integration and sustained premium margins. Rating Hold: a genuine transition story, but one priced for a best case rather than a margin of safety.
49/100
75Buffett
NICE Ltd: A Good Software Business Still Waiting for Proof That AI Adds More Than It Substitutes
NICE Ltd is a dual-engine, Nasdaq-listed enterprise software company: a cloud customer-engagement platform for contact centers and AI agents, paired with a financial-crime and compliance franchise built around Actimize. 2025 revenue reached $2.945 billion with 90% recurring revenue and a debt-free balance sheet, yet Q1 2026 non-GAAP cloud gross margin fell to 62.1% from 68.8% a year earlier, and management's Q2 guide of $761-771 million came in below the roughly $777 million consensus even as AI and self-service ARR grew 66% to $345 million. Rating Watch: the stock trades near a decade-low P/E of 9.5x with a genuinely strong balance sheet, but it is not yet clear whether AI is expanding NICE's revenue pool or substituting for the seats and minutes it once sold directly.